Chemotherapy-induced neuropathic pain

Area of Science:

• Oncology
• Neurology
• Pain Management

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and debilitating complication of anticancer therapies.
• CIPN significantly impacts cancer survivors' quality of life and can lead to treatment compromise.
• Understanding the underlying pathology of CIPN is crucial for developing effective treatments.

Purpose of the Study:

• To review the importance, clinical features, pathology, and treatments for chemotherapy-induced neuropathic pain.
• To specifically examine newer biological agents, such as bortezomib, in the context of CIPN.
• To highlight the under-recognized and undertreated nature of painful CIPN.

Main Methods:

• Review of current literature on chemotherapy-induced peripheral neuropathy.
• Analysis of clinical features and potential pathologies of CIPN.
• Evaluation of existing and emerging treatment strategies for CIPN, including newer agents like bortezomib.

Main Results:

• CIPN is a heterogeneous condition presenting distinct neuropathic pain profiles depending on the chemotherapy agent.
• Recent research has identified key processes involved in CIPN, offering potential avenues for novel treatments.
• Current evidence for the efficacy of common antineuropathic agents in treating CIPN is limited, necessitating further investigation.

Conclusions:

• Painful CIPN is often under-recognized and undertreated, posing a significant challenge during cancer treatment and in cancer survivors.
• Difficulties in assessment and treatment limitations contribute to the management problems associated with CIPN.
• Improved education for patients and clinicians, alongside enhanced assessment and treatment strategies, are essential to mitigate the debilitating effects of painful CIPN.